Archived: Taming Tetrazoles: How to Develop Robust Processes Safely. The Example of VT-1161
Date: 15 September 2022
Time: 15:00 (BST), 16.00 (CEST), 10.00 (EDT), 7.00 (PDT)
The demand for active substances for pharmaceutical and agrochemical applications is constantly increasing. Many chemical structures, used in innovative active ingredients, may be successfully synthesized with hazardous raw materials or process steps using hazardous chemistry. Although such reactions require specialized equipment, trained employees and precautions during development and manufacturing, they can have significant advantages in terms of efficiency, costs or even sustainability. To develop safe and robust commercial production processes, using hazardous chemistry, it is crucial to assess and manage the risks and hazards. An example of such a structured approach is shown for the development and manufacturing of VT-1161.
In this webinar, we speak about hazardous chemistry in the development of commercial scale processes to manufacture APIs. We focus on managing the risks of hazardous chemistry in order to develop safe and efficient processes on commercial scale. Based on a commercial active pharmaceutical ingredient – Oteseconazole/VT-1161 – we walk you through the project phases from development, scale-up to commercial manufacturing.
Why should you attend this webinar:
In this webinar, you will learn:
- How to identify and assess risks of potential hazardous substances and/or process steps
- How to handle hazardous chemistry in development, scale-up and production
- What safety tests and specialized equipment are required
- In what circumstances you might consider hazardous chemistry as a valuable tool, with a positive impact on efficiency, cost and sustainability
Who should attend:
- R&D process chemists
- Process engineers and process safety experts
- Managers / supervisors from R&D, production and chemical industries
- CMC / outsourcing managers
- HSE & QC managers
Dr. Jan Haller, R&D chemist, Novasep-PharmaZell, Leverkusen site, Germany
Jan Haller studied chemistry at the university of Kiel and received his PhD in organic chemistry in Münster in 1995. After a postdoc time at UCLA devoted to computational chemistry, he started his industrial career at Agfa (the former photo company) in the chemistry R&D department. Since 2001 his focus has moved to process development in the CDMO world of Novasep. Jan has successfully transferred an uncountable number of chemical steps to production.
Oliver Plietzsch, PhD, Head of R&D process development, Novasep-PharmaZell, Leverkusen site, Germany
Oliver Plietzsch received his PhD Degree in organic chemistry at Karlsruhe Institute of Technology in 2010. He has more than 10 years of experience in the chemical industry working for several global companies with positions in R&D, technical marketing, sales and operations. He joined Novasep in 2022 to lead the R&D and process safety department with focus on hazardous chemistry at the Leverkusen site.